REPLIGEN CORP Business Acquisition, Pro Forma Revenue
REPLIGEN CORP (RGEN) reported Business Acquisition, Pro Forma Revenue of $21.46 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2016-02-25
- REPLIGEN CORP business acquisition, pro forma revenue for the quarter ending 2015-06-30 was $21.46M, a 21.18% increase year-over-year.
- REPLIGEN CORP business acquisition, pro forma revenue for the quarter ending 2015-03-31 was $20.82M, a 14.11% increase year-over-year.
- REPLIGEN CORP business acquisition, pro forma revenue for the quarter ending 2014-12-31 was $67.28B, a 11.79% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma revenue for the quarter ending 2014-09-30 was $15.28M, a 25.54% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma revenue for fiscal 2014 was $67.33B, a 11.79% decline from fiscal 2013.
- REPLIGEN CORP business acquisition, pro forma revenue for fiscal 2013 was $76.33B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2015-06-30 | $21.46M 10-Q · filed 2015-08-06 | $42.27M 10-Q · filed 2015-08-06 | $67.32B derived: sum of 3 quarters · filed 2016-02-25 | $67.34B derived: sum of 4 quarters · filed 2016-02-25 | |
| 2015-03-31 | $20.82M 10-Q · filed 2015-05-08 | $67.30B derived: sum of 2 quarters · filed 2016-02-25 | $67.32B derived: sum of 3 quarters · filed 2016-02-25 | $67.33B derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-12-31 | $67.28B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $67.29B derived: sum of 2 quarters · filed 2016-02-25 | $67.31B derived: sum of 3 quarters · filed 2016-02-25 | $67.33B 10-K · filed 2016-02-25 | $67.33M 10-K · filed 2015-03-17 |
| 2014-09-30 | $15.28M 10-Q · filed 2015-11-05 | $32.98M derived: sum of 2 quarters · filed 2015-11-05 | $50.94M 10-Q · filed 2015-11-05 | $76.32B derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | $17.71M 10-Q · filed 2015-08-06 | $35.66M 10-Q · filed 2015-08-06 | $76.31B derived: sum of 3 quarters · filed 2016-02-25 | $76.33B derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | $18.24M 10-Q · filed 2015-05-08 | $76.29B derived: sum of 2 quarters · filed 2016-02-25 | $76.31B derived: sum of 3 quarters · filed 2016-02-25 | $76.33B derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | $76.27B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $76.29B derived: sum of 2 quarters · filed 2016-02-25 | $76.31B derived: sum of 3 quarters · filed 2016-02-25 | $76.33B 10-K · filed 2016-02-25 | $76.33M 10-K · filed 2015-03-17 |
| 2013-09-30 | $20.52M 10-Q · filed 2014-11-07 | $39.57M derived: sum of 2 quarters · filed 2014-11-07 | $57.86M 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $19.05M 10-Q · filed 2014-08-11 | $37.34M 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |